ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF
Summary
The USPTO published patent application US20260098078A1 covering activin receptor type II chimera polypeptides for treating conditions involving muscle weakness and atrophy, bone damage, blood disorders such as anemia, thrombocytopenia, and neutropenia, as well as fibrosis, metabolic disorders, and pulmonary hypertension. The application describes extracellular ActRII chimeras optionally fused to Fc domains as therapeutic agents.
What changed
The USPTO published patent application US20260098078A1 covering activin receptor type II chimera polypeptides and their use in treating conditions involving muscle weakness and atrophy, bone damage, low red blood cell levels, low platelet levels, low neutrophil levels, fibrosis, metabolic disorders, and pulmonary hypertension.
Pharmaceutical and biotechnology companies developing therapies for these therapeutic areas should monitor this application for competitive intelligence purposes and may need to evaluate potential licensing needs or design-around strategies if developing similar therapeutic candidates.
What to do next
- Monitor for updates
Archived snapshot
Apr 12, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF
Application US20260098078A1 Kind: A1 Apr 09, 2026
Inventors
Jasbir S. SEEHRA, Jennifer LACHEY, Claire TSENG, Jason O'NEILL, Henning THØGERSEN, Elissa FURUTANI
Abstract
The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, and/or pulmonary hypertension.
CPC Classifications
C07K 14/71 A61P 3/04 A61P 7/00 A61P 7/04 A61P 7/06 A61P 11/00 A61P 19/08 A61P 21/00 A61K 38/00 C07K 2319/30 C07K 2319/31
Filing Date
2025-12-10
Application No.
19415215
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.